Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond (Q89727324)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32061303%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

review article

1 reference

title

Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32061303%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

1 reference

Atanasio Pandiella

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32061303%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

Sara García-Alonso

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32061303%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

Alberto Ocaña

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32061303%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

publication date

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32061303%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32061303%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32061303%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32061303%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

page(s)

130-146

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32061303%20AND%20SRC:MED&resulttype=core&format=json

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

8 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Humanization of an anti-p185HER2 antibody for human cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Trastuzumab emtansine for HER2-positive advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and T

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Trastuzumab emtansine: mechanisms of action and drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Death through a tragedy: mitotic catastrophe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Mitosis is not a key target of microtubule agents in patient tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Resistance to Antibody-Drug Conjugates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Antibody-maytansinoid conjugates designed to bypass multidrug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Microtubules and resistance to tubulin-binding agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Strategies and challenges for the next generation of antibody-drug conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Next generation antibody drugs: pursuit of the 'high-hanging fruit'.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

NSCLC and HER2: between lights and shadows

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2019.12.010

10.1016/J.TRECAN.2019.12.010

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32061303%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32061303%20AND%20SRC:MED&resulttype=core&format=json